Project Grant R01AR084520
Award Date
7/1/25
Completion Date
4/30/30
Dollars Obligated
$528K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award of $187,938 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to support research that aims to uncover the origin of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). The grant recipient, The Johns Hopkins University, will use RA-derived monoclonal ACPAs to investigate the hypothesis that ACPAs may arise...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) worth $735,372 to Brigham & Women's Hospital Inc. on May 15, 2025. The project, titled "T Cell Expression of Inflammatory Chemokine Receptors," aims to identify transcription factors and cytokines that regulate the expression of chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in inflamed...
This federal Project Grant award, valued at $828,682 and awarded on September 24, 2024, supports research into population-based outcomes for rheumatoid arthritis (RA) in rural health settings. The funding is provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to investigate the challenges rural residents face in timely RA diagnosis and treatment...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a novel joint-targeted antibody therapy for the treatment of rheumatoid arthritis (RA). The award, totaling $402,086, will support the research team's efforts to synthesize new collagen hybridizing peptide (CHP) structures with high affinity to denatured collagen, and to...
This $506,085 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The primary focus is on evaluating the potential of obesity-induced inflammatory mediators, including proteins (adipokines) and lipids, to predict...
This federal Project Grant award, identified as R21AI190985, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $459,250 grant supports research to investigate the relationship between fibroblast-like synoviocytes (FLS) and endothelial cells (EC) in the synovium of rheumatoid arthritis (RA) patients. The research aims to validate a pathway connecting FLS transmigration with EC-mediated...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $553,248 to The Trustees of the University of Pennsylvania for research on INPP5E signaling and treatment approaches for rheumatoid arthritis (RA). The key objectives are to: 1) investigate how macrophage INPP5E expression impacts inflammation and bone erosion in RA, by analyzing...
This $143,949 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research aimed at defining how antibiotic-mediated gut dysbiosis and loss of certain short-chain fatty acid (SCFA)-producing bacteria alter intestinal and joint inflammatory responses. The 5-year project, led by Fang Roseanne Zhao, M.D., Ph.D. at Washington University, will use...